Teva Pharmaceutical (NYSE: TEVA) stock rose approximately 12.3% last week. The surge was primarily attributed to the company's second-quarter report, which showed sales of $4.1 billion, surpassing average analyst targets by roughly $70 million, and a softer-than-expected year-over-year revenue decline.

Additionally, Teva announced plans for a direct listing of its common stock on the New York Stock Exchange (NYSE), replacing its American Depositary Receipts (ADRs) starting September 14. This move is expected to attract institutional investors and retail traders.